Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.
Commenting about the trial during an interview, session cochair Dr Georg Schett (Medical University of Vienna, Austria) called the trial "an important story." He added that the findings confirm the ...
Biologic response modifiers presently approved in the USA for use in various rheumatic inflammatory diseases include three TNF inhibitors (etanercept, infliximab and adalimumab), a B-cell-directed ...
Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic ...
A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...
Researchers at University of Texas Release New Data on Rheumatoid Arthritis (Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence ...
In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this 12-part journey ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Since 2008, there has been no “consistent increase” in ...
SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback